Bellecapital International Ltd. Acquires 18,404 Shares of Pfizer Inc. (NYSE:PFE)

Bellecapital International Ltd. raised its holdings in Pfizer Inc. (NYSE:PFE) by 10.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 196,203 shares of the biopharmaceutical company’s stock after acquiring an additional 18,404 shares during the quarter. Pfizer comprises 1.1% of Bellecapital International Ltd.’s portfolio, making the stock its 28th largest position. Bellecapital International Ltd.’s holdings in Pfizer were worth $5,678,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Wealth Advisory Solutions LLC grew its stake in shares of Pfizer by 23.5% during the third quarter. Wealth Advisory Solutions LLC now owns 26,858 shares of the biopharmaceutical company’s stock worth $777,000 after purchasing an additional 5,117 shares during the period. Koss Olinger Consulting LLC boosted its holdings in Pfizer by 2.1% during the third quarter. Koss Olinger Consulting LLC now owns 78,381 shares of the biopharmaceutical company’s stock worth $2,268,000 after buying an additional 1,599 shares during the last quarter. Gilliland Jeter Wealth Management LLC grew its position in shares of Pfizer by 11.8% during the 3rd quarter. Gilliland Jeter Wealth Management LLC now owns 24,430 shares of the biopharmaceutical company’s stock worth $707,000 after buying an additional 2,579 shares during the period. Penn Davis Mcfarland Inc. bought a new stake in shares of Pfizer in the 3rd quarter valued at about $2,947,000. Finally, McClarren Financial Advisors Inc. increased its stake in shares of Pfizer by 2,381.0% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 4,838 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 4,643 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE traded down $0.29 during midday trading on Monday, reaching $28.93. The stock had a trading volume of 8,133,067 shares, compared to its average volume of 36,958,484. The firm has a market cap of $163.93 billion, a PE ratio of -483.67, a P/E/G ratio of 1.02 and a beta of 0.67. The firm has a 50 day simple moving average of $29.07 and a 200-day simple moving average of $28.45. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same period in the previous year, the firm earned $0.67 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 5.81%. Pfizer’s dividend payout ratio (DPR) is currently -2,800.00%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group lifted their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Wells Fargo & Company upped their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Barclays lifted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $33.91.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.